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Clinical and Procedural Effects of Transitioning to Contact Force
Guided Ablation for Atrial Fibrillation
Daniel R. Frisch1, Sean J. Dikdan1
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Abstract

Background: A major innovation in atrial fibrillation (AF) ablation has been the introduction of contact force (CF) sensing catheters.
Objective:To evaluate procedural and clinical effects of transitioning to CF-guided AF ablation.
Methods:Consecutive AF ablation patients were studiedduring the period of time of transitioning from a non-CF to CF sensing catheter.
Procedural data recorded was total radiofrequency time, time to isolate the left pulmonary veins (LPVs), and time to isolate the right
pulmonary veins (RPVs). Clinically, the 3 and 12-month maintenance of sinus rhythm was noted and compared by: paroxysmal vs. persistent
AF; CT scan LA volume more or less than 150 cc; CHA2DS2VASC more or less than 2; and LVEF more or less than 55%. Safety data was
recorded as well.
Results: Total ablation times were shorter (113 vs.146 min, p=0.011)when using the CF catheters compared to non-CF ablations. This was
driven by a decrease in both LPV (46 vs.72 min, p<0.001) and RPV time (54 vs. 75 min, p=0.002).The use of CF catheter did not change the
overall percentage of patients in sinus rhythm at 3 and 12-months of follow up. However, sinus rhythm was more frequent at 12 months with
CF ablation in patients with a LA volume of more than 150 cc when compared to non-CF ablation (84.6% and 52.4%, p=0.03). There was no
difference in outcomes with stratification by CHA2DS2VASC score or LVEF. No significant difference in complications was noted.
Conclusions:For AF ablation, the initial use of CF-sensing technology reduced procedure times with similar overall sinus rhythm
maintenance at 3 and 12 months. CF improved 12-month outcomes in patients with an enlarged LA.

Introduction

Electrical pulmonary vein isolation (PVI) for atrial fibrillation
(AF) is an established and effective therapy[1]. Clinical trials have
demonstrated that an ablation strategy is generally superior to
antiarrhythmic medications for the treatment of AF[2]. Radiofrequency
energy is the most common energy source used for ablation and is
often delivered in a point-by-point fashion around the pulmonary
veins. The original, non-irrigated catheters, recorded the temperature
via a thermistor at the tip of the catheter and measured impedance
changes over the duration of ablation. Later, irrigated catheters were
introduced for improved ablation efficacy and safety[3]. A limitation
of irrigated catheters is the inability to measure the temperature at
the tissue level of ablation due to the intentional cooling effect of the
irrigant on the catheter’s thermistor. The next major innovation in
ablation technology, which was approved by the FDA in 2014, was
the ability to measure catheter-tissue contact force (CF) in real-time
and to use that information to guide ablation. BiosenseWebseter’s
Smarttouch catheter was approved on February 25, 2014 and St. Jude
Medical’s TactiCath was approved on October 27, 2014[4,5]. The use
of contact force-guided ablation has been demonstrated to reduce
ablation gaps and improve ablation effectiveness[6,7,8].
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Once the CF catheters were approved at our institution we
adopted them into use for pulmonary vein isolation in place of the
irrigated, non-CF ablation catheters used previously. As with any
new technology, there was a requisite period of introduction and
transition. The purpose of this observational study was to assess
the impact of the single variable of incorporating CF technology
on procedural and clinical characteristics at the time of transition
to this technology. The hypothesis was that the introduction of CF
technology would improve both procedural and clinical aspects
of PVI. We expected that cases would take less time, require less
ablation, have fewer complications, and have better clinical outcomes
with CF technology. The other aspects of ablation, including the
ablation strategy, the personnel (a single attending electrophysiologist
working with one of three fellows depending on the academic year),
the other recording catheters, and the workflow remained the same.

Methods

This retrospective review included the period of time from July 2013
through November 2017, which was the time frame for collection
and follow up of 112 paroxysmal and persistent atrial fibrillation
patients referred for ablation. Patients eligible for this study included
consecutive patients who had undergone their first AF ablation with
CF catheters and the consecutive group of patients who underwent
their first AF ablation before CF catheters were available. Exclusion
criteria included patients who underwent ablation for arrhythmias
other than AF or who presented for a repeat procedure.
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Procedural and clinical characteristics were collected from our
institution’s electronic health record. Of the initial 112 patients
designated for inclusion in the study, 51 patients underwent non-CF
ablation and 61 underwent CF ablation; 7 patients in the non-CF
group and 10 in the CF group were excluded from analysis because
AF ablation was not performed or the presentation was for a repeat
ablation procedure. The data were collected and stored securely in
a password-protected database. The study was approved by our
institutional review board.

Catheter Ablation Procedure

All patients were referred for catheter ablation of AF and provided
written informed consent in accordance with institutional policy.
Antiarrhythmic medications other than amiodarone were stopped
three days before the procedure. In brief, femoral venous access was
obtained and a multipolar catheter was placed in the coronary sinus
and a diagnostic intracardiac ultrasound catheter (5.5 to 10 MHz;
AcuNav; Biosense Webster, Diamond Bar, California) was placed in
the right atrium. Two atrial transseptal punctures were performed,
and an ablation catheter and a circular mapping catheter (Spiral; St.
Jude Medical) were advanced into the left atrium. Three-dimensional
electroanatomic mapping was performed using the Velocity system
(St. Jude Medical).
All pulmonary veins were routinely isolated, typically as a pair.
Ablation was performed in the carina between ipsilateral veins
if isolation could not be achieved with wide area encirclement.
Radiofrequency ablation was delivered with a 3.5-mm openirrigated tip catheter or a 3.5-mm open-irrigated CF sensing catheter
(TactiCath; St. Jude Medical, St.Paul, MN). For LA volumes
exceeding 150 cc by cardiac CT a TactiCath 75 was used, and for a
volume less than 150 cc a TactiCath 65 was used[9]. With the nonCF catheter, radiofrequency was routinely delivered to lesions for 30
to 60 secondsto achieve a decrease in impedance of at least 5 to 10
Ohms at the ablation site. With the CF sensing catheter, ablation
was performed with a flow of 17 cc/minute, power 20-25 watts, a
goal of 10-40 g per lesion, and a goal of 400-500 g seconds per site
(typically a lesion size index 4.5-5.5). Successful PVI was defined by
the loss of all pulmonary vein potentials (entrance block) and failure
to capture the left atrium when pacing from sequential bipoles of the
circular mapping catheter placed at the ostium of each pulmonary
vein (exit block). Attempts at reinduction with burst pacing were
performedand recorded.
The rationale for the use of CF catheters and the working
parameters that we chose were determined by a number of published
investigations. The first was the 2012 TOCCATA study, which was
primarily a safety study for right and left atrial ablation using the same
CF ablation catheter used in our study[10]. Investigators identified a
force >100 g as a risk for perforation, which occurred in one patient.
The EFFICAS I trial (2013) was designed to assess CF (using the
TactiCath ablation catheter) and the ability to predict ablation gaps
during ablation for AF[11]. The operators were blinded to the contact
force data. The results established that a minimum CF (<10 g) and
minimum force-time integral (FTI; <400 gs) were predictors of gaps
in the ablation lesion set. To achieve durable lesions and to obtain
a successful PVI, a target CF of 20 g was recommended, with an
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absolute minimum CF of 10 g and an absolute minimum FTI of 400
gs per individual ablation lesion. The SMART AF trial (2014) was
designed for safety and effectiveness of the SmartTouch catheter[6].
In this trial, when the CF was between “investigator selected working
ranges” >80% of the time, outcomes were 4.25 times more likely
to be successful. In 2015, the EFFICAS II, which was designed
based on the findings in EFFICAS I with unblinded operators
using TactiCath, found that a CF of 20g and a minimum FTI of
400 gs reduced ablation gaps. The investigators found that fewer
lesions were required, and lower fluoroscopy times were achieved
with these parameters[12]. Finally, the TOCCASTAR study (2015)
randomizedCF vs. non-CF for paroxysmal AF and looked at 1 year
AF freedom after ablation (n=300) using TactiCath[7]. The authors
noted that when optimal CF was used (≥90% of the lesions with a
CF ≥10 g) outcomes were better (76% v. 58%) and fluoroscopy and
ablation times were less. Support for the use of ablation catheters
with CF parameters are supported by national guidelines[13].

Follow up

Patients in this practice tend to remain within the health system.
These patients were followed up periodically with routine office
visits at up 1, 3, 6, and 12 months and both in between visits and
beyond 12 months if there was a reportof symptoms. Standard
electrocardiography was performed at each follow-up visit to assess
AF status. Mobile cardiac outpatient telemetry monitors were used
if indicated clinically. Phone calls and emails were encouraged with
any symptoms. At 12-month follow up, data was able to be collected
on 30 patients in the non-CF group and 38 patients in the CF group.

Study Endpoints

The primary procedural endpoints were total radiofrequency
time, time to complete isolation of the left pulmonary veins, time
to complete isolation of the right pulmonary veins, and inducibility
to AF, atrial flutter, or other arrhythmias. The primary clinical
endpoints were the presence of AF during the first 3 and first 12
months. Recurrence of AF was defined as 30 seconds or more of
symptomatic or asymptomatic AF after ablation regardless of the
pre-procedural burden or the patient’s perception of improvement
after the procedure.

Results

Baseline characteristics of the 95 included patients did not show
any significant differences [Table 1]. The sample was predominantly
men around the age of 60. Persistent AF comprised a larger proportion of the sample (60%)than paroxysmal AF.

Procedural Results

For the procedural analysis, data was complete for 86 patients. In
each of the categories measured, there was a reduction in procedural
time and total radiofrequency application time when a CF catheter
was used [Table 2]. Theuse of a CF catheter significantly reduced
the mean total ablation time by about 33 minutes (1 hour and 53
minutes compared to 2 hours and 26 minutes, p=0.011). LPV and
RPV times were both significantlyshorter in the CF ablation group
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as well[Figure 1]. There was no difference in the ability to reinducesustained atrial fibrillation, non-sustained atrial fibrillation, or other
arrhythmias between catheter types [Table 3].

Clinical Results

We chose 2 time points to evaluate for AF recurrence: 3 months—
frequently considered the blanking period—and 12 months after
ablation. No differencein the percentage of patients in sinus rhythm
was detected between the CF and non-CF groups (74.5% and
Patient demographics and baseline data

Table 1:

score or LVEF.

Safety Results

Overall, there was no observed increase in complications with the
introduction of CF ablation. Pericardial effusion with or without the
need for pericardiocentesis occurred in 3/45 = 7% of patients prior
Table 3:

Arrhythmia Inducibitily. Independent two samples two-tailed
t-test of left, right, and total ablation time by catheter used.
Contact Force
(N=46)

Non-Contact Force
(N=37)

Chi-squared

P value

Non-inducible

21

13

0.094

.30

AF

6

8

.33

Non-sustained AF

2

3

.47

Contact Force
(N=51)

Non-Contact Force
(N=44)

p-value

Age, years mean (STD)

60.7 (9.8)

60.3 (8.8)

0.60

Typical AFL

17

9

.22

Male gender, no. (%)

40 (78.4)

29 (65.9)

0.13

Atypical AFL

0

4

.02

Paroxysmal AF, no. (%)

21 (41.2)

17 (38.6)

0.48

CHA2DS2-VASc score median (IQR)

1 (1-2)

2 (1-3)

0.24*

Anti-arrhythmic drug use, no. (%)

16 (31.4)

10 (22.7)

0.24

Anticoagulation use, no. (%)

24 (47.1)

23 (52.3)

0.38

3D LA volume, mL

162.3 (39.9)

165.6 (46.3)

0.26

Left Ventricular Ejection Fraction, %

56.6 (13.3)

55.0 (15.8)

0.29

* The nonparametric Wilcoxon rank-sum test was used to analyze CHA2DS2-VASc score, as
median instead of mean were being compare.

* Inducibility testing was not performed on 2 patients in the Contact Force group and 3 patients in
the non-Contact Force group. These are excluded.
** Bonferroni correction method was used to correct for multiple comparison post-hoc (adjust
p-value=0.05/5= 0.01). No significant differences were found.

Table 4a:

Clinical Outcomes. Patients in sinus rhythm after 3-months based
on disease characteristics and catheter used.*
Contact Force
(N=51)

Non-Contact Force
(N=44)

P value

Overall patients in sinus rhythm, % (n)

78.4 (40)

68.2 (30)

0.26

Type of AF

Paroxysmal

71.4 (15)

70.6 (12)

1.00

Persistent

83.3 (25)

66.7 (18)

0.22

≥ 150

76.9 (20)

61.9 (13)

0.34

< 150

80 (20)

73.9 (17)

0.74

CHA2DS2VaSc
score

≥2

82.6 (19)

64.0 (16)

0.20

<2

75.0 (21)

73.7 (14)

1.00

LVEF, %

≥ 55

78.4 (29)

80.0 (24)

1.00

< 55

78.6 (11)

42.9 (6)

0.12

LA volume, cc

* Chi-square used for overall analysis while fisher’s exact test used for subgroup comparisons as
some cells contained numbers <10

Table 4b:
Figure 1:

Clinical Outcomes. Patients in sinus rhythm after 12-months
based on disease characteristics and catheter used.*

Graph of total, left pulmonary vein, and right pulmonary vein
ablation time by catheter used.
Procedural Times. Independent two samples two-tailed t-test of
left, right, and total ablation time by catheter used.

Table 2:

Total Ablation Time

LPV Time

Contact
Force

Non-Contact
Force

Contact
Force

Non-Contact
Force

Contact
Force

Non-Contact
Force

N

47

39

47

40

47

39

Mean

1:53:24

2:26:16

0:45:51

1:12:07

0:54:41

1:14:43

STD

1:03:38

0:51:11

0:24:44

0:33:55

0:25:28

0:31:33

p-value

0.011

Non-Contact Force

P value

Overall patients in sinus rhythm, % (n)

74.5 (38)

68.2 (30)

0.50

Type of AF

Paroxysmal

61.9 (13)

82.4 (14)

0.28

Persistent

83.3 (25)

59.3 (16)

0.08

≥ 150

84.6 (22)

52.4 (11)

0.03

< 150

64.0 (16)

82.6 (19)

0.20

CHA2DS2VaSc
score

≥2

73.9 (17)

64.0 (16)

0.54

<2

75.0 (21)

73.7 (14)

1.00

LVEF, %

≥ 55

73.0 (27)

73.3 (22)

1.00

< 55

78.6 (11)

57.1 (8)

0.42

RPV Time

<0.001

0.002

* All comparisons were found to be statistically significant.

68.2%, respectively; p=0.50) at the 3-month follow up period [Table
4a]. The overall 12-month incidence of sinus rhythm was also not
significantly different [Table 4b]; [Figure 2]). Subgroup analysis done
at 12-month follow up showed that sinus rhythm was more frequent
with CF compared to non-CF in patients with an LA volume greater
than 150 cc compared (84.6% and 52.4%, respectively; p=0.03). There
was no difference in outcomes with stratification by CHA2DS2VASC
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Contact Force

LA volume, cc

*Chi-square used for overall analysis while fisher’s exact test used for subgroup comparisons as
some cells contained numbers <10

to the introduction of CF catheter and in 1/52 = 2% of the patients
who underwent ablation with a CF catheter (p=0.24). There were no
strokes, deaths, bleeding episodes requiring transfusion, esophageal
injuries, or phrenic nerve injuries in either group.

Discussion

The intent of this study was to quantify the impact of the
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introduction of CF technology at the time of transition to this
technology on procedural and clinical aspects of PVI. The ablation
strategy, techniques, and workflow were the same but the catheter,
specifically the ability to measure CF, was different. This strategy
minimized confounding by other variables (e.g. changing the ablation
strategy, the ablation modality, or the primary operator).
The main findings in this study of transitioning to the use of contact
force catheters for atrial fibrillation ablation are that (1) procedure
times, ablation times, and time to pulmonary vein isolation is reduced

Figure 2:
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Forest plot comparing patients in sinus rhythm at 12 months
based on catheter used and atrial fibrillation characteristics.

when contact force catheters are used; (2) clinical outcomes are
similar, and perhaps improved in patients with large LA volumes;
and that (3) complications rates were not increased.
As is the case with introduction of many new technologies, a learning
curve is often required to become comfortable and demonstrate
proficiency, thus maximizing the benefit of the innovation. Clearly,
if new technology is difficult to use or if it is associated with
complications it is unlikely to succeed. With the introduction of
the contact force parameter there was a novel ablation parameter to
follow. At times the tactile feel of the catheter would be discordant
to the measured force. That is, the feeling of “heavy” force sometimes
equated to a low force readings and vice versa. Confidence in the
contact force recordings and calibration sometimes meant deciding
which parameter (tactile feel or recorded force) represented the
optimal ablation scenario. Because of this unfamiliar dilemma due to
inexperience, we were reminded of the so-called “July phenomenon”
(when there is a perceived decrease in the quality of health care at
the start of the North American academic year for medical training)
[14]
. Although the July phenomenon has been largely refuted,an
abundance of evidence that “surgeon volume” matters across a range
of operations including electrophysiology procedures[15,16].
We found that, somewhat paradoxically, the initial use of a new
ablation catheter improved procedural time and some effectiveness
endpoints immediately, without the benefit of a large volume of
cases. This reassured us about any concerns we had about slowing
our workflow. Measuring contact force added usable information
to the ablation strategy, and it also reduced ablation times, which
ultimately improved workflow. The decreased procedural duration
times were apparent almost immediately with adoption the contact
force technology. Prior studies have shown a decrease in procedural
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time, but without differentiating between LPV and RPV times[17,18].
Our study found that patients with large LA volumes (which we
defined based on a previous investigation)undergoing AF ablation
with a CF catheter were more likely to remain in sinus rhythm at 12
months[9]. This difference was driven by two CF patients converting
to sinus between the 3 and 12 month period and two non-CF patients
who convert from sinus back to AF in the same time period.One
long term study has shown PV reconnection in both CF and non-CF
ablated patients owing primarily to the RPV that negated a significant
difference in atrial arrhythmia free survival[19]. CF ablation has been
shown to improve outcomes in patients with paroxysmal AF in large
studies[20-22] and subsequent research on persistent AF has shown a
benefit as well[23]. Patients with exclusively persistent AF and large
LA enlargement, however,have been shown not to have an increase
in sinus rhythm at 12 months[24]. Our analysis did not compare these
two covariates directly, and it is possible that the advantage seen in
our study was due to patients with large LA volumes and specifically
paroxysmal AF.
Our complication rates were low in both arms, and similar to those
of other studies involving CF ablations[23,24]. Larger studies with
longer follow up have seen a reduction in complications with CF
ablation so it is possible that we lacked significant enough power to
detect a difference in complication rate[24].
This study has several limitations. First, the sample size is small.
Despite initially selecting 112 charts, only 68 patients who met
inclusion criteria completed their 12-month follow up. The patients
lost to follow up appear in proportion between both the CF and nonCF group, but nevertheless this may result in unintended selection
bias. Second, despite outpatient telemetry monitoring and regular
electrocardiography it remains possible that patients had recurrences
that asymptomatic and unrecorded. Third, subgroup analysis was not
performed on procedural outcomes. Certain patient characteristics
may have impacted procedural times. Finally, mean times to perform
each AF ablation were reported. Changes in procedural time may
have occurred towards the end of the CF group as the operator
became more familiar with technology.

Conclusions

For atrial fibrillation ablation, introduction of CF-sensing
technology reduced procedure times with similar overall sinus
rhythm maintenance at 12 months. Notably, CF improved 12-month
outcomes in patients with an enlarged left atrium.
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